Bcl9L Antibody

Blue Ice

Predicted: 165 kDa
Observed: 195 kDa

Bcl9L Antibody: Bcl9L, a homolog of Bcl9, was initially identified through a bioinformatics screening. It is expressed in fetal brain, adult lung, eye and prostate, in addition to several types of tumors including pancreatic and prostate cancers. Bcl9L has been shown to interact with beta-catenin, a target of the Wnt signaling pathway, and is required for enhanced beta-catenin-T-cell factor (TCF)-mediated transcription in colorectal tumor cells, possibly by translocating beta-catenin to the nucleus. Other studies have indicated that Bcl9L expression correlates with high nuclear grade cancer phenotype and the expression of ErbB2/HER-2 in breast cancers, suggesting that activity may occur in other types of cancer. Bcl9L has also been shown to be critical for Wnt-mediate regulation of stem cell traits in colon epithelium and adenocarcinomas which are associated with tumor invasion, metastasis, and resistance to therapy.

Trial Size

32698936

PRS-1201-0.1mg

1 mg/mL

Bcl9L antibody can be used for detection of Bcl9L by Western blot at 1 μ g/mL. Antibody can also be used for immunohistochemistry starting at 5 μ g/mL and immunocytochemistry starting at 10 μ g/mL. For immunofluorescence start at 20 μ g/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.

Bcl9L antibody is predicted to not cross-react with other Bcl family members. At least four isoforms of Bcl9L are known to exist; this antibody will detect all four.

Polyclonal

Homo sapiens

Optimal dilutions for each application to be determined by the researcher.